Radiopharm Theranostics, Ltd

RADX · Nasdaq · Australia

Share price · RADX

$0.69-1.94 (-73.85%) 3M

close as of 2026-11-18 · 24h delayed · vol 19K (0.4x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when RADX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 29 Oct 2026+17.5%
  2. 5 Oct 2026-10.6%
  3. 15 Sep 2026-24.4%
  4. 28 Jul 2026-9.6%
  5. 24 Jul 2026-17.2%
  6. 26 Jun 2026-7.2%
  7. 24 Jun 2026-5.5%
  8. 5 Jun 2026-6.7%
  9. 13 May 2026+8.7%
  10. 6 May 2026-7.4%

Share of unusual movement by asset

For each asset, the share of RADX's own-move activity since 4 Dec 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
RAD101
events and moves
94%
RAD202
events and moves
5shown from 8 days
177Lu-BetaBart
events and moves
3shown from 8 days
177Lu-RAD204
events and moves
2shown from 8 days
Assets with fewer than 8 event days, together—1%
Other company news (earnings, financing, releases naming no asset)—67%
Sessions with no dated event—28%

Assets

(4 total)
4Total Assets
0Approved
0Phase 3 / Filed
4Phase 1–2 / Early
3Diseases
Quick filter:
Showing 4 of 4 assets
Target & Modality
Phase 2
Fatty acid synthase (FASN)Radiopharmaceutical
Brain Metastases
Phase 1/2
B7-H3Radiopharmaceutical
Non-Small Cell Lung Cancer
Phase 1
PD-L1Radiopharmaceutical
Non-Small Cell Lung Cancer
Phase 1
HER2Radiopharmaceutical
Solid Tumors
HER2-Positive Advanced Solid Tumors

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
December 2027 (1)
177Lu-BetaBartPhase 1/2Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer, NSCLC (Non-small Cell Lung Cancer), Ovarian Cancer, Cervical Cancer …
Est. primary completion 2027-12 · NCT07189871 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

22 July 2026Topline resultRAD101RAD101 Phase 2b meets primary endpoint
US · Radiopharm Theranostics, Ltd · Source ↗

Financial reports

Annual history (3 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$3.6M$28M$29M$9.6M-$37M operating cash flowreport ↗
View 2 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$0.3M$23M$19M$12M-$23M operating cash flowreport ↗
2023-FY$0.3M$23M$12M$8.7M-$23M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-10-19Voliotis Dimitris · Chief Medical OfficerAward / grant (derivative)10,295,667——Form 4
2026-10-19Voliotis Dimitris · Chief Medical OfficerAward / grant (derivative)10,295,667——Form 4
2026-10-19Voliotis Dimitris · Chief Medical OfficerAward / grant (derivative)10,295,666——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 7 reporting institutions held 51.3M shares ($2.1M).

#InstitutionSharesValue
1SILVERARC CAPITAL MANAGEMENT, LLC187,406$806K
2Stonepine Capital Management, LLC51,000,000$739K
3HSBC HOLDINGS PLC61,372$265K
4Regal Partners Ltd40,138$173K
5PNC FINANCIAL SERVICES GROUP, INC.16,000$69K
6UBS Group AG3,000$13K
7RHUMBLINE ADVISERS121$519